Bcl-2 expression restores the leukemogenic potential of a BCR/ABL mutant defective in transformation
- PMID: 11090078
Bcl-2 expression restores the leukemogenic potential of a BCR/ABL mutant defective in transformation
Abstract
Growth factor-dependent hematopoietic cell lines expressing the BCR/ABL oncoprotein of the Ph chromosome show growth factor-independent proliferation and resistance to apoptosis. Apoptosis resistance of BCR/ABL-expressing cells may depend on enhanced expression of anti-apoptotic proteins as well as reduced expression and/or inactivation of pro-apoptotic proteins. Compared to myeloid precursor 32Dcl3 cells expressing wild type BCR/ABL, cells expressing a BCR/ABL mutant lacking amino acids 176-426 in the BCR domain (p185 delta BCR) are susceptible to apoptosis induced by interleukin-3 (IL-3) deprivation. These cells exhibited the hypophosphorylated apoptotic BAD and markedly reduced levels of Bcl-2. Upon ectopic expression of Bcl-2, these cells showed no changes in BAD phosphorylation, but they became apoptosis-resistant and proliferated in the absence of IL-3, albeit more slowly than cells expressing wild type BCR/ABL. Moreover, the p185 delta BCR/Bcl-2 double transfectants were leukemogenic when injected into immunodeficient mice, but Bcl-2 expression did not restore the leukemia-inducing effects of p185 delta BCR to the levels of wild type BCR/ABL. Leukemic cells recovered from the spleen of mice injected with p185 delta BCR/Bcl-2 cells did not show rearrangements in the Bcl-2 genomic locus, but they exhibited enhanced proliferation in culture and induced a rapidly fatal disease process when inoculated in secondary recipient mice. Together, these data support the importance of anti-apoptotic pathways for BCR/ABL-dependent leukemogenesis and suggest that Bcl-2 expression promotes secondary changes leading to a more aggressive tumor phenotype. (Blood. 2000;96:3915-3921)
Similar articles
-
Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant.J Exp Med. 1998 Jun 15;187(12):1995-2007. doi: 10.1084/jem.187.12.1995. J Exp Med. 1998. PMID: 9625759 Free PMC article.
-
Versatility of BCR/ABL-expressing leukemic cells in circumventing proapoptotic BAD effects.Blood. 2000 Jul 15;96(2):676-84. Blood. 2000. PMID: 10887134
-
BCR/ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac.Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11858-62. doi: 10.1073/pnas.95.20.11858. Proc Natl Acad Sci U S A. 1998. PMID: 9751755 Free PMC article.
-
The SH3 domain contributes to BCR/ABL-dependent leukemogenesis in vivo: role in adhesion, invasion, and homing.Blood. 1998 Jan 15;91(2):406-18. Blood. 1998. PMID: 9427693
-
Molecular biology of chronic myeloid leukemia.Int J Hematol. 2001 Apr;73(3):308-22. doi: 10.1007/BF02981955. Int J Hematol. 2001. PMID: 11345196 Review.
Cited by
-
Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts.Wien Klin Wochenschr. 2003 Aug 14;115(13-14):485-504. doi: 10.1007/BF03041033. Wien Klin Wochenschr. 2003. PMID: 13677268 Review.
-
Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor.Proc Natl Acad Sci U S A. 2003 May 27;100(11):6523-8. doi: 10.1073/pnas.0731871100. Epub 2003 May 15. Proc Natl Acad Sci U S A. 2003. PMID: 12750477 Free PMC article.
-
Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells.Br J Pharmacol. 2008 Feb;153(4):657-68. doi: 10.1038/sj.bjp.0707608. Epub 2007 Dec 3. Br J Pharmacol. 2008. PMID: 18059320 Free PMC article.
-
Association of promoter polymorphisms of Fas -FasL genes with development of Chronic Myeloid Leukemia.Tumour Biol. 2016 Apr;37(4):5475-84. doi: 10.1007/s13277-015-4295-0. Epub 2015 Nov 13. Tumour Biol. 2016. PMID: 26563376
-
Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic _target.Leukemia. 2013 Oct;27(10):1996-2005. doi: 10.1038/leu.2013.151. Epub 2013 May 14. Leukemia. 2013. PMID: 23670294 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous